Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
BUSINESS
AZ Japan Sees Combo Holding Promise in Immuno-Oncology Race, Set to Triple Oncology Sales in 5 Years
Dave Fredrickson, the new Japan chief of AstraZeneca, expressed his confidence on October 25 that his company could catch up with rivals in the immuno-oncology (IO) space by capitalizing on its combination therapy of two internally developed IO compounds. “We…
To read the full story
Related Article
- AZ Boosting Field Force Specialization with Move to Business Units: Japan Chief
April 19, 2017
- Dave Fredrickson Tapped as Next Chief of AstraZeneca Japan
June 13, 2016
- AZ Set to Double Japan Sales by 2020 on Cancer Meds, No Patent Cliff in Sight: Local Pres. Baertschi
May 11, 2016
- AZ Eyes Low Single-Digit Growth over Coming Years in Japan: Pres. Baertschi
November 16, 2015
BUSINESS
- Chiba Downpours Cause No Major Disruption to Drug Operations
August 17, 2026
- Chugai Files Tecentriq for Colon Cancer Adjuvant Therapy in Japan
August 17, 2026
- Enflonsia Filed for High-Risk Children in 2nd RSV Season in Japan: MSD
August 17, 2026
- Healios to File MultiStem in Japan Without Waiting for PIII Results: CEO
August 17, 2026
- Taiho’s Zipalertinib Hits Primary Goal in 1st Line NSCLC Trial
August 17, 2026
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…